Moors & Cabot, Inc. Abb Vie Inc. Call Options Transaction History

Moors & Cabot, Inc.

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 04, 2023	SELL	$144.61 - $166.54 $57,844 - $66,616	-400 Reduced 80.0%	100 $15,000
Q4 2022 Feb 09, 2023	BUY	$138.31 - $165.87 $69,155 - $82,935	500 New	500 $80,000
Q3 2022 Nov 07, 2022	BUY	$134.21 - $153.93 $67,105 - $76,965	500 New	500 $2,000
Q2 2020 Aug 13, 2020	SELL	$73.37 - $98.18 $2.41 Million - $3.23 Million	-32,900 Reduced 94.0%	2,100 $7,000
Q3 2019 Oct 22, 2019	BUY	$62.98 - $75.72 $2.2 Million - $2.65 Million	35,000 New	35,000 $27,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Moors & Cabot, Inc., based on Form 13F filings with the SEC.

Stay updated on Moors & Cabot, Inc. with notifications on news.